NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT01915498 2024-10-22Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCelgenePhase 1/2 Completed345 enrolled 120 charts 1 FDA
NCT02113982 2024-08-01Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaStemline Therapeutics, Inc.Phase 1/2 Completed138 enrolled 23 charts 1 FDA